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Abstract
Background: Implementation of self-management support in traditional primary care settings has proved difficult,
encouraging the development of alternative models which actively link to community resources. Chronic kidney disease
(CKD) is a common condition usually diagnosed in the presence of other co-morbidities. This trial aimed to determine the
effectiveness of an intervention to provide information and telephone-guided access to community support versus usual
care for patients with stage 3 CKD.
Methods and Findings: In a pragmatic, two-arm, patient level randomised controlled trial 436 patients with a diagnosis of
stage 3 CKD were recruited from 24 general practices in Greater Manchester. Patients were randomised to intervention (215)
or usual care (221). Primary outcome measures were health related quality of life (EQ-5D health questionnaire), blood
pressure control, and positive and active engagement in life (heiQ) at 6 months. At 6 months, mean health related quality of
life was significantly higher for the intervention group (adjusted mean difference = 0.05; 95% CI = 0.01, 0.08) and blood
pressure was controlled for a significantly greater proportion of patients in the intervention group (adjusted odds-
ratio = 1.85; 95% CI = 1.25, 2.72). Patients did not differ significantly in positive and active engagement in life. The
intervention group reported a reduction in costs compared with control.
Conclusions: An intervention to provide tailored information and telephone-guided access to community resources was
associated with modest but significant improvements in health related quality of life and better maintenance of blood
pressure control for patients with stage 3 CKD compared with usual care. However, further research is required to identify
the mechanisms of action of the intervention.
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Introduction
Self-management support is seen as a priority for people with
long-term health problems and primary care has been identified as
an important site of delivery [1] [2]. However implementation in
traditional primary care settings has proved difficult, encouraging
the development of alternative models [3] [4] [5] [6] [7] [8]. This,
together with evidence that health-related phenomena (such as
smoking cessation and weight loss) spread across social networks
[9], suggests the need for a paradigm shift in how to support
people with long-term health problems [1] [10].
Rather than focussing exclusively on individual factors such as
self-efficacy and behaviour, self-management support might better
utilize personal networks and resources within the community
[11]. Self-management support undertaken within and utilising
the social networks of people living with long-term conditions
draws on a broader set of resources including practical and
emotional support (‘illness work’) [11] [12] [13] [14]. This
approach which focuses on personal communities and resources
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highlights the centrality of relationships in self-management, such
as friends and family, and the importance of encouraging links
within local communities which lie outside formal healthcare. This
has the advantage of potentially building sustainable strategies for
self-management over the long term, which may be of particular
benefit to socially disadvantaged communities who have struggled
to engage with traditional models of self-management support
[15]. These populations are likely to be more amenable to self-
management support options, which are more closely aligned to
their everyday lives and personal preferences [11] [12] [14].
Effective management of CKD may prevent progression of the
disease, and reduce the risk of cardiovascular disease [16] [17]. As
emphasised by NICE guidance in the management of CKD, a key
element of recommended practice is to offer high quality
education at appropriate stages of the person’s condition to enable
understanding and informed choices about treatment [17]. It is
recommended that information should be tailored to their stage
and cause of CKD, any complications and the risk of progression.
However, whilst discussions around CKD may be viewed as a
platform to address vascular risk and support lifestyle change,
concerns have also been raised over unnecessary disease labelling,
with both general practitioners and practice nurses having
expressed a reticence to disclose a diagnosis of stage 3 CKD
[18] [19] [20] [21] [22]. This includes a need to underplay CKD,
with efforts focused on reassuring patients, particularly in older
people and patients with CKD stage 3A [22]. This tension is
reflected in inconsistent use of disease registers for patients who
fulfil the criteria for CKD, evidence of infrequent clinical
discussions about CKD, as well as low patient awareness of early
stage CKD [23] [24] [25] [26]. Chronic kidney disease is also
patterned by socio-economic deprivation, is usually diagnosed in
the presence of other co-morbidities. CKD is therefore a good
exemplar to explore the possibilities of innovative community and
network focused models of self-management [27] [28] [29] [30].
This trial was conducted as part of a wider programme of work
that aimed to improve health care and reduce inequalities in
health for people living with chronic vascular conditions (http://
clahrc-gm.nihr.ac.uk/). A key element of the programme was to
improve links between different providers of support for health,
including professionals, voluntary, and community resources in
order to widen the options of self-management support [31]. This
approach emphasises the support for people with long-term
conditions outside conventional services, and the distinction
between professionally-defined and patient-defined priorities in
the management of long-term conditions. With a particular focus
on the interface between primary care and resources in the
community, the BRinging Information and Guided Help Togeth-
er (BRIGHT) intervention aimed to explore the potential of
network focused self-management support in the context of CKD.
The BRIGHT intervention was delivered to patients with stage 3
CKD and aimed to: 1) provide patient information that
incorporated both clinical and lay knowledge; 2) provide
telephone-guided help by lay health workers to support patient
access to community support; and 3) broaden the scope of self-
management support by tailoring access to local community
resources [14].
The primary aim of the trial was to test whether an intervention
which provides information about self-management, tailored
access to local community resources and telephone-guidance can
improve health outcomes for patients with stage 3 CKD.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The trial was approved by NRES Committee NorthWest
Greater Manchester Central reference: 11/NW/0855. Partici-
pants provided their written consent to participate in this study.
We conducted a pragmatic, two-arm, patient level randomised
controlled trial to test whether this model of self-management
support is effective and cost-effective compared to usual primary
care for patients with a diagnosis of stage 3 CKD. Intervention
and trial design were informed by the principles of minimally
disruptive medicine [32] and sought to ensure that: CKD was
understood and prioritised from a patient perspective; it built on
rather than disrupted existing clinical dialogue; it prioritised
linkage with community resources; and recognised that CKD is a
condition that is rarely diagnosed in isolation but rather needs to
be discussed in the context of managing other risk factors and co-
morbidities [27]. Full details of the protocol have been published
elsewhere (see protocol S1) [14].
The trial was registered 5 months after recruitment of patients
started, due to an error in the application of our procedures.
Registration was completed during the recruitment period, and
prior to follow up, analysis of the data and interpretation. Patient
recruitment and follow-up took place between April 2012 and
November 2012. Patients were recruited from practice CKD
registers. Patients provided their written consent to participate in
this study. The authors confirm that all ongoing and related trials
for this intervention are registered.
Population and setting
Eligible patients were registered with 24 general practices in
Greater Manchester. This included 13 practices that participated
in a renal collaborative project established by CLAHRC for
Greater Manchester designed to improve identification and
management of patients with CKD [33]. Patients coded with an
existing clinical diagnosis of stage 3 CKD (both stages 3a and 3b,
with and without proteinuria) were eligible and invited through the
practice registers at GP practices. Participating general practices
provided data on stage of CKD including evidence of proteinuria
according to the disease classification system for CKD outlined in
2008 NICE guidance. Patients were excluded if they were unable
to communicate in English, had reduced capacity to provide
informed consent or were in receipt of palliative care. Only one
person per household was eligible to take part to avoid potential
contamination. Areas for practice recruitment were chosen
because they served some of the most deprived populations of
the UK: 20.4% of participants lived in the 20% most deprived
local areas in England [34].
Telephone contact was made by a member of the practice team
to patients due to be seen for a vascular disease review and/or if
the GP or nurse prefered, through raising the study at the end of
the consultation. These patients were informed about the
BRIGHT trial and asked if their contact details could be
forwarded to the BRIGHT team for them to be contacted for
further information. If patients agreed to participate a meeting
with a researcher was arranged and the first part of the
questionnaire was sent.
The BRIGHT intervention was designed to align with patients’
routine disease review appointments conducted by participating
general practices. Informed consent and baseline data collection
The BRIGHT Randomised Controlled Trial for Patients with Stage 3 CKD
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was carried out by a member of the research team, where possible
subsequent to a patient’s disease review appointment at their
general practice so that we could ensure blood pressure readings
were collected at or as near to baseline as possible and to ensure
practices had the opportunity to discuss CKD diagnosis with
patients prior to the trial. Recruitment took place between April
and November 2012 and 637 eligible patients identified by
practices agreed to be contacted by a researcher. The number of
patients approached to be involved with the study were frequently
requested by the trial team but unfortunately this information was
very patchy and so it is not possible to report accurately.
Intervention
The intervention entailed provision of a kidney information
guidebook; a booklet and interactive website that tailored access to
community resources; and telephone-guided help from a lay
health worker. Details of the BRIGHT intervention are detailed in
the published study protocol [14].
The kidney information guidebook. The ‘Keeping Your
Kidneys Healthy’ guidebook was developed in response to findings
that emerged during an initial study, which identified a need for an
information resource to support patients diagnosed with stage 3
CKD [22]. This was developed with patients with stage 3 CKD
and provided information based on the experiences of patients,
their expressed information needs and medical evidence about
treatment options. The process of development followed estab-
lished principles [35] [36] [37]. The guidebook was intended to
encourage patients to consider changes they could make to
maintain general vascular health in the context of having a
diagnosis of early stage CKD.
PLANS: Tailored access to community resources. The
PLANS (Patient-Led Assessment for Networks Support) booklet
and website have been designed to address the range of health and
social problems related to living with a long-term health problem
[38]. PLANS is a needs-led self-assessment tool for users to assess
and prioritise their health and social needs, with links to relevant
community resources and local support (collated in a database and
aligned via the website to the PLANS questions). As well as
offering lifestyle options (weight management classes, exercise
groups, etc.), PLANS has been designed to increase social contact
and promote community support awareness and engagement to
sustain independent living. Patients who received the intervention
were given access to the PLANS website and also given a PLANS
booklet. The telephone support guided participants through the
PLANS questions and options on the database.
Telephone facilitation from a lay health worker. The
telephone facilitation model was informed by a systematic review
of telephone-based self-management interventions to prevent and
manage vascular disease conducted by members of the BRIGHT
team [39]. Two telephone calls from a lay health worker were
delivered to patients in the intervention arm; one call at one-week
post-administration of the kidney information guidebook and the
PLANS booklet, followed by another call four-weeks later. For the
first call, a lay health worker guided patients through the PLANS
booklet and website and discussed the PLANS results (e.g. local
groups and resources). PLANS and the telephone support were
designed to focus on patients’ needs, everyday living arrange-
ments, and personal preferences. For example, patients were asked
to provide background information about themselves including
how they felt they were coping with their health; living
circumstances (e.g. married, family, etc); personal and social
interests and current social activity. Patients were then taken
through the online PLANS questionnaire by a telephone support
worker to identify needs and preferences related to wellbeing,
health education, adult learning, support, independent living and
volunteering opportunities. Following this they were offered a set
of results of local activities and services. Brief descriptions of these
results were given to patients who were then asked if they were
interested in any further information about any of the groups,
activities or services. Hence, the intervention was tailored to meet
the expressed needs of patients based on their personal preferences
and the background information provided. After the first
telephone call, information about the groups, activities or services
were sent to the patient. For the second call, patients were asked if
they had tried any of the recommended activities and were offered
another opportunity to complete the PLANS questionnaire.
Telephone support was available (Monday to Friday) throughout
the course of the trial for unscheduled enquiries from patients.
Lay health workers participated in a three-hour training session
facilitated by CB (who led the development of PLANS) about how
to facilitate appropriate referrals to local resources. For the
training, lay health workers received a detailed workbook and
guidance on how to deliver the intervention by telephone. There
were 8 telephone support workers: 3 members of staff, 4
postgraduate students, and one undergraduate student at the
University of Manchester. One support worker (PJ) was employed
specifically to oversee the delivery of the telephone support. Most
of the support workers had a limited background in health and
social care and all but one were psychology graduates.
Participants in the control arm were sent the kidney information
guidebook and the PLANS booklet with links to the website at the
end of the trial period. Both arms had usual access to primary
care.
Sample size
We powered the study to have 80% power to detect a
standardised effect size of 0.25 between the control and
intervention arms on any continuous outcome measure. This also
provided 80% power to detect a change of at least 10% in the
percentage of patients achieving blood pressure control. These are
relatively small effects, but in line with most sizes of effect observed
in our previous trials of self-management interventions [40] [41].
Basing power on an alpha level of 0.05 and a regression analysis
treating outcome measures at baseline as a covariate correlated at
0.5 with follow-up (a conservative estimate), and 25% attrition of
participants, we aimed to recruit between 16 and 18 general
practices and a total of 500 patients across these. In the event, we
recruited a higher number of practices, 24, but a slightly lower
number of patients, 436, though due to a lower than anticipated
attrition rate, without any loss of power.
Randomisation
Immediately after consent and baseline data collection, an
independent clinical trials unit was contacted by telephone and the
participant was allocated to receive either the intervention or usual
care (1:1) via a minimisation algorithm. The minimisation
procedure ensured that within each practice, as each subsequent
patient was recruited the two trial arms remained well-balanced on
three key prognostic factors (age, smoking status and evidence of
other vascular disease). The method also includes a degree of
random allocation to avoid complete determination.
Outcomes
We collected patient level outcomes at baseline and at six
months. We had three primary outcomes: positive and active and
engagement in life, blood pressure control; and health related
quality of life. Engagement was measured using the ‘The Positive
and Active Engagement in Life’ domain of the validated Health
The BRIGHT Randomised Controlled Trial for Patients with Stage 3 CKD
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Education Impact Questionnaire (heiQ) [42] because the item
content fitted with the goal of the intervention which was to
provide access to meaningful support and rewarding activities.
The items are:
N I am doing interesting things in my life
N Most days I am doing some of the things I really enjoy
N I try to make the most of my life
N I have plans to do enjoyable things for myself.
N I feel like I am actively involved in life
As stated by Osborne et al. ‘this scale assesses motivation to be
active and embodies the notion of participants in self-manage-
ment/patient education programs engaging or re-engaging in life-
fulfilling activities as a result of program involvement. Items in this
construct aim to measure the individuals’ activities to convert
intention into positive outcomes, and implies a change of lifestyle
and life activities.’ [42]
Blood pressure was dichotomised as ‘controlled’ versus poorly
controlled in accordance with 2008 NICE guidance [17] on the
management of CKD for patients with stage 3 CKD with and
without proteinuria (i.e. ,140/90 for patients without proteinuria
and ,130/80 for patients with proteinuria). Blood pressure
recordings were collected from general practice records; we used
the readings taken closest to date of randomisation and 6 month
follow up. Generic health related quality of life was measured
using the EuroQoL EQ-5D index of health-related quality of life
(three-level version) [43].
Secondary outcomes included: an additional five domains of the
heiQ (social integration and support, skill and technique acquisi-
tion, emotional wellbeing, self-monitoring and insight, and health
service navigation); the Summary of Diabetes SelfCare Activities
Measure (SDSCA) [44]; the anxiety sub-scale from the Hospital
Anxiety and Depression Scale (HADS-A) [45], and as a measure
of CKD-specific anxiety the Emotional Response item from the
Brief Illness Perception Questionnaire (BIPQ) in relation to the
patient’s CKD [46]; four physical and psychological well-being
health education outcome measures taken from the Medical
Outcomes Study (general health, social role/limitation, energy/
vitality and psychological wellbeing) [47]; the UCLA Loneliness
Scale [48]; the Medication Knowledge and Medication Motiva-
tion subscales from the Modified Morisky Medication Adherence
Scale (MMMAS) [49]; Social capital [50] service use (frequency of
contact with primary care services and hospital outpatient
services); and levels of Illness, practical everyday and emotional
work done by social network members (see Protocol S1). [14]
With the exception of blood pressure which was measured by a
health care professional at a clinic, all outcomes were administered
by post and collected by a researcher. Neither the researchers nor
health care practitioners were blinded to allocation.
Service utilisation measured primary health care (GP home and
practice visits, pharmacy), community health and social care,
secondary health care services, out of pocket costs and costs of lost
productivity. Unit cost estimates were then applied to these
resource use data to generate patient level cost estimates. The cost
of developing and delivering the intervention were also estimated.
Statistical analysis
Analysis followed intention to treat principles and a pre-
specified plan (see analysis plan S1). Binary outcomes (i.e. blood
pressure control) were analysed using logistic regression and
continuous outcomes using linear regression, using robust standard
errors adjusted for the clustering of patients within practices. We
controlled for baseline values of each outcome, design (i.e.
minimisation) factors (age-group, smoking status, additional
vascular disease) and self-report of CKD as an additional pre-
specified covariate. We applied multiple imputation (MI) to
baseline and 6 month variables with missing values by the chained
equations approach using scores on all primary and secondary
outcomes (at baseline and follow-up), CKD stage, patient
demographics (age, gender, education, area deprivation, smoking
status) and comorbidities. We used 20 MI sets, as examination of
Monte Carlo errors indicated that this provided stability of results
[51].
MI was adopted for the main analysis because this provides less
biased estimates of effect than those from complete cases analysis
[51] but a sensitivity analysis was conducted based on complete
cases. We also conducted a further post-hoc sensitivity analysis to
examine stability against two blood pressure related factors. First,
the NICE criteria for blood pressure control differs between
patients with and without diabetes or proteinuria; second, we
found wide variation in the dates of patient routine blood pressure
readings relative to dates of randomisation and 6 month follow-up
[17]. To test the stability of our results to these factors we repeated
the primary analysis including covariates for presence of diabetes/
proteinuria and for length of time between baseline and follow-up
blood pressure readings. Where either sensitivity analysis produced
a result differing in significance from the primary analysis, this is
indicated in the text and tables.
Analyses were conducted using STATA IC (version 12.1) with
an alpha significance value of 5%. For outcomes with skewness or
kurtosis $1.5, we used standard errors based on 1000 boot-
strapped samples to derive confidence intervals and p values. We
report effect sizes standardised on baseline standard deviations
across all participants.
Cost effectiveness analysis
Utilisation and Resource use. Resource use data and
EQ5D data were collected using patient questionnaires at baseline
and 6 month follow up. Missing data was imputed using multiple
imputation methods. Unit cost estimates were applied to relevant
resource use data to generate a total cost per patient (post-
randomisation). Quality Adjusted Life Years (QALYs) were
generated by applying the UK ‘‘tariff’’ [52] to EQ5D responses
and used the Area under the Curve method with adjustment for
baseline scores on the EQ5D [53]. Cost and QALY data were
then synthesised to calculate an Incremental Cost Effectiveness
Ratio (ICER).
Results
Figure 1 presents the trial CONSORT diagram. 34 practices
were initially approached and 10 practices declined to participate
in the trial prior to data collection. 440 patients were recruited
from 24 GP practices (mean list size; 5815 patients) with an
average of 18 patients per practice. Subsequently, 4 patients were
excluded post-randomisation because they were identified as not
meeting the criteria of having stage 3 CKD. Their registered GPs
and the patients were informed. In total, 436 patients completed
baseline data and 374 (85.7%) patients returned 6 month follow up
data. We excluded two baseline blood pressure readings taken
more than 15 months prior to randomisation; all other blood
pressure readings were within 6 months of the target dates, with an
average deviation of minus 27 days at baseline and minus 17 days
at 6 month follow up.
The BRIGHT Randomised Controlled Trial for Patients with Stage 3 CKD
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Baseline characteristics of study participants
58.5% (n= 255) of patients were female and few patients were
non-white (1.4%). The mean age of patients was 72.1 years and
41.7% (n= 182) of patients had co-morbid established cardiovas-
cular disease. Just over half of patients did not self-report CKD
(52.1%, n= 227) (table 1).
Engagement with intervention
The intervention comprised of the kidney information guide-
book, the telephone service and the PLANS booklet and/or
interactive website aimed at encouraging patients to contact and
participate in local community activities or services. In summary,
82.2% (n= 147) of the 179 intervention patients who returned 6-
month follow-up data reported using the ‘Keeping Your Kidneys
Healthy’ guidebook at least once and 91.9% (n= 135) of these
Figure 1. Trial CONSORT Diagram.
doi:10.1371/journal.pone.0109135.g001
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Table 1. Baseline characteristics of participants.
Characteristics BRIGHT intervention (n =215) Usual care (n =221) Total (n =436)
Gender:
Male 90 (41.9) 91 (41.2) 181 (41.5)
Female 125 (58.1) 130 (58.8) 255 (58.5)
Mean age in years (SD): 72.4 (9.2) 71.8 (9.0) 72.1 (9.1)
Age group:
,75 years 118 (54.9) 132 (59.7) 250 (57.3)
75 years or older 97 (45.1) 89 (40.3) 186 (42.7)
CKD Stage:
3a2proteinuria 156 (72.6) 156 (70.6) 312 (71.6)
3a+proteinuria 8 (3.7) 10 (4.5) 18 (4.1)
3b2proteinuria 37 (17.2) 39 (17.7) 76 (17.4)
3b+proteinuria 14 (6.5) 16 (7.2) 30 (6.9)
Education:
No qualifications 104 (49.5) 84 (39.3) 188 (44.3)
1 or more O levels 18 (8.6) 19 (8.9) 37 (8.7)
1 or more A levels 3 (1.4) 10 (4.7) 13 (3.1)
NVQ/other trade/professional 64 (30.5) 90 (42.1) 154 (36.3)
Degree 21 (10.0) 11 (5.1) 32 (7.6)
Ethnicity:
White 202 (98.1) 213 (99.1) 415 (98.6)
Non-white 4 (1.9) 2 (0.9) 6 (1.4)
Mean Index of multiple deprivation (SD) (Higher score =greater
deprivation):
21.9 (15.2) 23.4 (17.5) 22.7 (16.4)
Co-morbid established cardiovascular disease (Angina, Irregular heartbeat, Stroke, PVD, heart failure):
No 126 (58.6) 128 (57.9) 254 (58.3)
Yes 89 (41.4) 93 (42.1) 182 (41.7)
Diabetes:
No 166 (77.2) 169 (76.5) 335 (76.8)
Yes 49 (22.8) 52 (23.5) 101 (23.2)
No of co morbid long-term conditions (excluding kidney problems):
0 3 (1.4) 2 (0.9) 5 (1.2)
1–2 63 (29.3) 68 (30.8) 131 (30.1)
3–4 102 (47.4) 90 (40.7) 192 (44.0)
5–6 30 (14.0) 49 (22.2) 79 (18.1)
7+ 17 (7.9) 12 (5.4) 29 (6.7)
Smoker:
No 198 (92.1) 201 (91.0) 399 (91.5)
Yes 17 (7.9) 20 (9.1) 37 (8.5)
Recruited from collaborative practice:
No 87 (40.5) 87 (39.4) 174 (39.9)
Yes 128 (59.5) 134 (60.6) 262 (60.1)
Mean General Health score (SD): 2.8 (0.9) 2.7 (1.0) 2.8 (0.9)
Self-report CKD:
No 111 (51.6) 116 (52.5) 227 (52.1)
Yes 104 (48.4) 105 (47.5) 209 (47.9)
Blood pressure control:
Uncontrolled 66 (31.0) 57 (25.9) 123 (28.4)
Controlled 147 (69.0) 163 (74.1) 310 (71.6)
Mean heiQ, positive and active engagement in life (SD): 64.6 (19.7) 65.6 (18.5) 65.1 (19.1)
Mean EQ-5D (SD): 0.67 (0.30) 0.67 (0.30) 0.67 (0.30)
The BRIGHT Randomised Controlled Trial for Patients with Stage 3 CKD
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patients reported that they found it ‘useful’ or ‘very useful’.
Furthermore, 87.2% (n= 156) of patients reported that the kidney
information guidebook was ‘easy to read’ and 48% (n= 86)
reported that the guidebook made them ‘feel less anxious’
(table 2).
Overall, 94.4% (n= 203) of patients in the intervention arm
received an initial telephone support call and 97.5% (n= 198) of
these received a follow up support call 4 weeks later. 62% (n= 111)
of patients reported that they found the telephone support call
‘useful’ or ‘very useful’ and 40.2% (n= 72) stated that the call
encouraged them to ‘think about trying local activities’.
Around a quarter of patients reported accessing the website
(26.3%, n= 47) and 66.5% (n= 119) reported that the PLANS
booklet was ‘useful’ or ‘very useful’. Forty (22.3%) patients
contacted at least one PLANS group, 28 (15.6%) attended at
least one PLANS group and 14 (7.8%) reported that they were
currently attending at least one PLANS group at 6-month follow-
up.
Analysis of outcomes
In analyses of primary outcomes, blood pressure was within
NICE guidance for a significantly greater proportion of patients in
the intervention group at 6 months, relative to baseline (adjusted
odds-ratio = 1.85; 95% CI= 1.25, 2.72) (table 3). Mean health
related quality of life was also significantly higher for the
intervention group (adjusted mean difference = 0.05; 95%
CI= 0.01, 0.08). However, patients in the intervention group did
not differ significantly on positive and active engagement in life
[42]. These results were confirmed by a sensitivity analysis using
complete cases and a further post-hoc analysis adjusted for
differing sub-group criteria for blood pressure control and differing
times of measurement.
Figure 2 depicts the unadjusted rates of blood pressure control
for the two groups, across time. The rate of control remained
stable in the intervention group over the 6 months, but dropped
very considerably in control patients, suggesting that the effect of
the intervention was to help patients maintain, but not increase,
blood pressure control. Mean systolic and diastolic blood pressure
in intervention patients changed very little over the 6 months (from
131.6 to 131.5 and 73.6 to 73.4 respectively), but increased in
control patients (129.0 to 135.2 and 73.4 to 74.5 respectively). For
health related quality of life however, there was an increase in
mean score for intervention patients, compared to no change in
the control group mean (Figure 3).
Analysis of secondary outcomes (table 3) indicated that patients
in the intervention group reported significantly higher levels of
self-care activity at 6 months compared to control patients
(adjusted mean difference = 0.23; 95% CI= 0.04, 0.41). In
contrast to our hypothesis, patients in the intervention group
experienced a significant reduction in practical work undertaken
by their social network at 6 months (adjusted mean difference =
22.02; 95% CI=23.68, 20.36). All results remained unchanged
under both sensitivity analyses, with the exception of a significant
(p,0.05) increase in energy/vitality scores for intervention
patients under complete cases analysis.
Cost effectiveness. Based on a multiple imputation analysis,
there were statistically significant differences between the groups in
terms of Quality Adjusted Life Years generated over the 6 month
time horizon of the trial. The absolute difference, in favour of the
BRIGHT intervention, of 0.012 QALYs (95%CI 0.002 to 0.022)
after adjustment including baseline EQ5D scores would be
considered statistically significant at conventional levels. Again
based on multiple imputation data, the intervention group was
associated with a reduction in costs compared with control due to
lower secondary care attendance. The mean difference in total
cost was £175 (95%CI 2£284 to £635). Control groups costs
were inflated by two individuals spending 60+ days as inpatients.
However, even when these are removed, the intervention is
associated with reduced costs (mean difference £123, 95% CI 2
£103 to £349). Results from the multiple imputation were
consistent with the complete case analysis, where again QALYs
were significantly higher in BRIGHT group and costs were
reduced.
Discussion
Principal findings of the study
The BRIGHT intervention used tailored information and
telephone-facilitated help to enhance self-management by sign-
posting patients to community resources. The intervention was
associated with modest but significant improvements in health
related quality of life and better blood pressure control, which was
maintained in the intervention arm but not in the control arm.
However, with the exception of a small increase in self-care
activities, these effects were not matched by improvements in
patient-reported positive and active engagement in life.
These modest but significant benefits occurred in the context of
relatively limited engagement with some aspects of the interven-
tions. Relatively few patients in the intervention arm of the trial
reported engagement with a PLANS group, with only 7.8%
reporting attending at least one PLANS group at 6-months. This
data might suggest that the PLANS component was ineffective and
could be omitted from the intervention. We argue that would be
premature. It is difficult to remove individual components from a
complex intervention without potentially threatening the effec-
tiveness of the whole. Qualitative work conducted as part of the
BRIGHT trial [54] shows that the PLANS and telephone-guided
help components of the intervention were more challenging for
patients, and also provided some evidence that the process
encouraged positive action by giving patients the opportunity to
reflect on their current circumstances. A better focus may be on
enhancing the intervention, by increasing the number of follow up
consultations, or providing supported access to groups (such as
transport). However, lack of clarity about the causal mechanisms
suggests that further work is needed to explore these issues before
more widespread commissioning can be recommended.
Strengths and limitations of this study
The intervention is a generic model that could be adapted for
any chronic condition, but CKD was selected because of its
Table 1. Cont.
Characteristics BRIGHT intervention (n =215) Usual care (n =221) Total (n =436)
Mean service use in previous 6 months (SD): 7.4 (7.1) 8.1 (14.1) 7.8 (11.2)
Values are number (percentage) unless stated otherwise.
doi:10.1371/journal.pone.0109135.t001
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Table 2. Intervention uptake and evaluation.
Outcome Total intervention group 6mfu data (n =179)
Kidney booklet uptake
How useful did you find the ‘Keeping your kidneys healthy booklet’:
Very useful or useful 150 (83.8)
Not very useful or useful at all 8 (4.5)
Didn’t use 17 (9.5)
Missing 4 (2.2)
How often did you refer to the ‘Keeping your kidneys healthy booklet’:
Used occasionally or now and then 81 (45.3)
Used only once 66 (36.9)
Haven’t used 27 (15.1)
Missing 5 (2.8)
Kidney booklet evaluation
The ‘Keeping your kidneys healthy booklet’ was easy to read:
Strongly agree or agree 156 (87.2)
Neither agree nor disagree 11 (6.2)
Disagree or strongly disagree 1 (0.6)
Missing 11 (6.2)
The ‘Keeping your kidneys healthy booklet’ made me feel less anxious:
Strongly agree or agree 86 (48.0)
Neither agree nor disagree 65 (36.3)
Disagree or strongly disagree 15 (8.4)
Missing 13 (7.3)
The ‘Keeping your kidneys healthy booklet’ helped me discuss care with my doctor:
Strongly agree or agree 101 (56.4)
Neither agree nor disagree 53 (29.6)
Disagree or strongly disagree 12 (6.7)
Missing 13 (7.3)
The ‘Keeping your kidneys healthy booklet’ helped me understand how the NHS will support my care:
Strongly agree or agree 117 (65.4)
Neither agree nor disagree 44 (24.6)
Disagree or strongly disagree 3 (1.7)
Missing 15 (8.4)
The ‘Keeping your kidneys healthy booklet’ enabled you to cope with life:
Much better or better 70 (39.1)
Same or less 74 (41.3)
Missing/not applicable 35 (19.6)
The ‘Keeping your kidneys healthy booklet’ enabled you to understand your condition:
Much better or better 93 (52.0)
Same or less 56 (31.3)
Missing/not applicable 30 (16.8)
The ‘Keeping your kidneys healthy booklet’ enabled you to cope with your condition:
Much better or better 80 (44.7)
Same or less 63 (35.2)
Missing/not applicable 36 (20.1)
The ‘Keeping your kidneys healthy booklet’ enabled you to keep yourself healthy:
Much better or better 93 (52.0)
Same or less 57 (31.8)
Missing/NA 29 (16.2)
The ‘Keeping your kidneys healthy booklet’ enabled you to feel confident about your health:
Much more or more 69 (38.6)
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Table 2. Cont.
Outcome Total intervention group 6mfu data (n =179)
Same or less 79 (44.1)
Missing/NA 31 (17.3)
The ‘Keeping your kidneys healthy booklet’ enabled you to help yourself:
Much more or more 74 (41.3)
Same or less 72 (40.2)
Missing/NA 33 (18.4)
Telephone support call uptake:
How useful did you find the telephone support call:
Very useful or useful 111 (62.0)
Not very useful or useful at all 14 (7.8)
Didn’t use 47 (26.3)
Missing 7 (3.9)
Telephone support call evaluation:
I would like to use this type of service again:
Strongly agree or agree 47 (26.3)
Neither agree nor disagree 86 (48.0)
Disagree or strongly disagree 29 (16.2)
Missing 17 (9.5)
I felt the conversation with the telephone support worker was relevant to me:
Strongly agree or agree 91 (50.8)
Neither agree nor disagree 59 (33.0)
Disagree or strongly disagree 15 (8.4)
Missing 14 (7.8)
I felt the conversation with the telephone support worker understood my needs and concerns:
Strongly agree or agree 99 (55.3)
Neither agree nor disagree 58 (32.4)
Disagree or strongly disagree 7 (3.9)
Missing 15 (8.4)
The conversation encouraged me to think about trying local activities:
Strongly agree or agree 72 (40.2)
Neither agree nor disagree 64 (35.8)
Disagree or strongly disagree 28 (15.7)
Missing 15 (8.4)
The conversation was easy to follow:
Strongly agree or agree 131 (73.2)
Neither agree nor disagree 28 (15.6)
Disagree or strongly disagree 4 (2.2)
Missing 16 (8.9)
Website uptake:
How useful did you find the website:
Very useful or useful 41 (22.9)
Not very useful or useful at all 14 (7.8)
Didn’t use 108 (60.3)
Missing/not applicable 16 (8.9)
How many times did you visit the website?:
Used occasionally or now and then 18 (10.1)
Used only once 29 (16.2)
Haven’t used 90 (50.3)
Missing/not applicable 42 (23.5)
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association with socioeconomic deprivation as well as controversies
over the relevance of the condition to patients and practitioners.
The majority of patients with stage 3 CKD are managed in
primary care and though effective self-management support is
highlighted as a key aspect of care for this practice population [17],
thus far there has been limited research and evidence on how to
achieve this [55]. Intervention and study design was informed by
the principles of minimally disruptive medicine [32] in order to
support the embedding and integration of recruitment for the
BRIGHT intervention with primary care procedures. We
achieved high levels of participation by general practices.
Respecting GP judgement on eligibility, 440 out of 637 (69%)
potential participants agreed to take part in the trial. In addition,
participant self-report indicated that the components of the
intervention were both acceptable and useful.
We recognise that the provision of information may also be
relevant to patients with CKD stages 1 or 2 with proteinuria, who
are also at increased cardiovascular risk [16]. However, for trial
purposes, in order to be confident of recruiting patients with a
recorded diagnosis, we limited recruitment to patients with stage 3
CKD - a stage incentivised by the Quality and Outcomes
Framework of the new General Medical Services contract [56].
Table 2. Cont.
Outcome Total intervention group 6mfu data (n =179)
Website evaluation:
I found the website easy to use:
Strongly agree or agree 26 (14.5)
Neither agree nor disagree 52 (29.1)
Disagree or strongly disagree 12 (6.7)
Missing/not applicable 89 (49.7)
I found the website relevant to me:
Strongly agree or agree 14 (7.8)
Neither agree nor disagree 62 (34.6)
Disagree or strongly disagree 13 (7.3)
Missing/not applicable 90 (50.3)
PLANS booklet uptake:
How useful did you find the PLANS booklet:
Very useful or useful 119 (66.5)
Not very useful or useful at all 29 (16.2)
Didn’t use 26 (14.5)
Missing 5 (2.8)
PLANS groups uptake:
Total number of PLANS groups patient’s contacted:
0 101 (56.1)
1–2 34 (18.9)
3+ 6 (3.4)
Missing 6 (3.3)
Not applicable - No group information requested 33 (18.3)
Total number of PLANS groups patient’s attended:
0 108 (60.0)
1 19 (10.6)
2 6 (3.3)
3 3 (1.7)
Missing 11 (6.1)
Not applicable - No group information requested 33 (18.3)
Total number of PLANS groups patient’s currently attending:
0 122 (67.8)
1 10 (5.6)
2 2 (1.1)
3 2 (1.1)
Missing 11 (6.1)
Not applicable - No group information requested 33 (18.3)
Values are number (percentage).
doi:10.1371/journal.pone.0109135.t002
The BRIGHT Randomised Controlled Trial for Patients with Stage 3 CKD
PLOS ONE | www.plosone.org 10 October 2014 | Volume 9 | Issue 10 | e109135
Table 3. Results of regression analyses of primary and secondary outcomes at 6 months.
Unadjusted mean (SD); N
Outcome
BRIGHT
intervention1 Usual care1
Adjusted mean
difference2
(95% CI) P Value2 Effect size2
Effect size from
complete cases
analysis1
Primary Outcomes
Blood pressure control 67.3%3; 193 55.3%3; 210 1.854 (1.25, 2.72) 0.002* 1.854 (1.25,
2.72)
1.904 (1.28, 2.83)
Positive and active
engagement with life
(heiQ) positive and active
engagement in life Higher
score = higher engagement
with life
66.4 (19.7); 180 66.5 (17.6); 194 0.00 (23.20, 3.21) 0.999 0.00 (20.16,
0.16)
20.01 (20.17, 0.16)
Health-related Quality of
Life (EQ-5D)
0.71 (0.28); 179 0.67 (0.29); 193 0.05 (0.01, 0.08) 0.027* 0.16 (0.03,
0.29)
0.18 (0.06, 0.30)
Secondary Outcomes
heiQ, social integration and
support Higher score =
Higher social integration
69.6 (20.3); 178 69.4 (15.6); 193 0.78 (21.70, 3.26) 0.537" 0.05 (20.10,
0.20)
0.01 (20.16, 0.19)
heiQ, skills and technique
acquisition Higher
score = Higher skills and
technique acquisition
65.4 (14.6); 177 65.0(13.1); 192 1.49 (20.88, 3.85) 0.218" 0.10 (20.06,
0.27)
0.13 (20.05, 0.31)
heiQ, emotional wellbeing
Higher score = Higher
negative affect
31.4 (22.2); 180 34.0 (22.2); 194 21.85 (25.75, 2.05) 0.329 20.09 (20.25,
0.07)
20.09 (20.25, 0.07)
heiQ, self-monitoring and
insight Higher score =Higher
self monitoring and insight
70.7 (12.2); 180 70.7 (11.5); 194 0.47 (21.65, 2.58) 0.644 0.04 (20.11,
0.20)
0.03 (20.13, 0.18)
heiQ, health services
navigation Higher score =
higher health service
navigation
70.5 (16.2); 179 69.4 (15.9); 193 1.88 (21.28, 5.04) 0.226 0.14 (20.06,
0.34)
0.12 (20.08, 0.32)
SelfCare Activities (SDSCA)
Higher score = higher
self-care
4.5 (1.2); 172 4.2 (1.2); 191 0.23 (0.04, 0.41) 0.019* 0.20 (0.06,
0.34)
0.17 (0.05, 0.29)
Anxiety (HADS-A) Higher
score = greater anxiety
4.6 (3.7); 179 5.2 (4.1); 194 20.51 (21.05, 0.02) 0.060 20.14 (20.28,
0.01)
20.14 (20.27, 0.00)
CKD-specific anxiety (BIPQ
Emotional Response item
asked in relation to CKD)
(6 months only) Higher
score = greater anxiety
1.2 (2.0); 179 1.6 (2.2); 190 20.46 (20.97, 0.05) 0.073 20.21 (20.42,
0.00)
20.18 (20.39, 0.02)
MOS, General Health Higher
score = Better general health
2.8 (1.0); 179 2.8 (0.9); 193 0.01 (20.12, 0.14) 0.832 0.01 (20.12,
0.14)
20.02 (20.14, 0.10)
MOS, Social/Role Activities
Limitations Higher
score = LOWER social
limitations
73.2 (28.2); 177 68.7 (30.5); 194 1.85 (23.68, 7.37) 0.492 0.06 (20.10,
0.22)
0.05 (20.13, 0.22)
MOS, Energy/Vitality Higher
score = higher energy and
vitality
52.4 (22.0); 179 50.8 (21.8); 194 2.77 (20.39, 5.93) 0.082 0.13 (0.00,
0.26)
0.16 (0.04, 0.28)
MOS, Psychological
Wellbeing Higher
score = higher psychological
wellbeing
74.7 (18.8); 179 74.0 (19.9); 193 1.28 (21.18, 3.73) 0.286 0.06 (20.06,
0.18)
0.08 (20.04, 0.19)
Loneliness (UCLA Loneliness
Scale) Higher score = LOWER
loneliness.
30.3 (5.3); 177 31.0 (4.4); 192 20.06 (20.82, 0.69) 0.861 20.01 (20.15,
0.14)
20.01 (20.15, 0.14)
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Participation was restricted to patients able to read and
understand English so we cannot assume that the findings of this
study would be similar for patients in whom English is not their
first language. None of the staff who delivered the intervention had
clinical training (though one was a member of the research team
and all but one were psychology graduates), and the BRIGHT
training was brief. If the intervention was to be rolled out, it is
likely that it could be delivered by a range of staff, including staff in
voluntary groups, more established lay health workers such as
health trainers, or telecare staff.
Limitations of the study are that a longer follow-up would have
been preferable to show if the improvements could be sustained.
The trial used validated instruments to measure health related
quality of life and positive and active engagement in life [42] [52],
though we recognise there is potential for bias in patient self-report
outcomes in an unblinded trial. Resource use was also collected
using patient questionnaires at baseline and follow up, which is a
potential limitation as self-report may not always agree with
sources such as service records. Blood pressure measurement was
based on routine data collection rather than formal research
assessments, and there was also a small difference in retention rates
between arms. However, we used robust allocation concealment,
achieved high levels of retention overall, and used appropriate
imputation to account for missing data, and have no reason to
doubt that the blood pressure outcomes are valid. Nevertheless,
caution is required with interpretation of the blood pressure
outcome, since the mechanism of action remains unclear. There
were no significant differences between the two arms of the study
in terms of positive and active engagement in life (primary
outcome), GP and nurse visits, or medication adherence (second-
ary outcomes). We did not collect data on prescribing of
antihypertensive medication, which is a potential limitation in
understanding mechanisms of action though an effect was
observed on self-management activities (secondary outcomes)
using a validated measure that assesses diet, exercise and smoking
behaviour. The intervention was intended to facilitate greater
engagement with community groups and resources, but contrary
to our original hypothesis, in addition to no significant effect in
positive and active engagement in life, levels of support from
personal social networks (for practical work) were significantly
reduced in the intervention arm. One plausible explanation is that
intervention patients felt enabled to do more for themselves, thus
reducing dependence on others: high dependency has negative
emotional effects and greater autonomy is a desired objective of
many people with limiting health problems [57]. A better
understanding of the mechanisms by which these innovative
network interventions achieve their effects is a key research
question for the future.
Table 3. Cont.
Unadjusted mean (SD); N
Outcome
BRIGHT
intervention1 Usual care1
Adjusted mean
difference2
(95% CI) P Value2 Effect size2
Effect size from
complete cases
analysis1
MMMAS, Medication
knowledge (6 months
only) Higher score = higher
medication knowledge
2.6 (0.6); 175 2.6 (0.6); 191 20.05
(20.16, 0.05)
0.331" 20.09
(20.26, 0.09)
20.07 (20.26, 0.12)
MMMAS, Medication
motivation (6 months only)
Higher score = higher
medication motivation
2.7 (0.6); 177 2.7 (0.5); 192 20.03
(20.13, 0.07)
0.568" 20.06
(20.25, 0.14)
20.05 (20.25, 0.16)
Social capital: Health Survey
for England Higher
score = greater satisfaction
with opportunities to
participate in the community
3.7 (0.8); 178 3.6 (0.8); 188 0.08
(20.08, 0.23)
0.325 0.09
(20.08, 0.26)
0.09 (20.08, 0.25)
Service use 6.1 (5.5); 180 6.5 (4.7); 194 20.30
(21.10, 0.49)
0.455" 20.03
(20.10, 0.04)
20.03 (20.1, 0.04)
Social network – Illness
work Higher score = greater
help with illness work from
social network
10.3 (8.4); 160 11.5 (9.0); 182 21.18
(23.02, 0.66)
0.208" 20.21
(20.54, 0.12)
20.24 (20.61, 0.13)
Social network – Practical
work Higher score = greater
help with practical work
from social network
6.2 (6.2); 159 8.1 (7.1); 176 22.02
(23.68, 20.36)
0.017*" 20.46
(20.83, 20.08)
20.53 (20.93, 20.12)
Social network – Emotional
work Higher score = greater
help with emotional work
from social network
13.4 (10.4); 163 14.9 (11.4); 182 20.67
(22.47, 1.12)
0.463" 20.09
(20.31, 0.14)
20.13 (20.35, 0.09)
1Values from complete cases.
2Values from multiple imputation analysis.
3Percentage of patients with controlled blood pressure.
4Adjusted odds ratio.
"P value based on boot strapped estimate of variance.
*Significant at p,0.05.
doi:10.1371/journal.pone.0109135.t003
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Comparison with other studies and key implications of
the research
The BRIGHT trial aimed to connect people to resources in
order to support vascular health and broader wellbeing, and builds
on growing evidence that diverse and supportive networks can
improve health [9]. This approach values support provided
outside healthcare settings, though it may be important that such
support is legitimised by a GP or nurse [58]. Our intervention may
have created a critical moment or tipping point for patients.
Perhaps this method of increasing awareness of CKD gave control
to the patient enabling them to initiate responses or actions.
A recent meta-analysis highlighted the importance of blood
pressure lowering as an effective strategy for reducing cardiovas-
cular events in people with CKD [59]. Our results demonstrated
deterioration in blood pressure control in usual care patients and
maintenance of control in those receiving the intervention, but the
comparative benefits were similar in magnitude to structured care
in general practice for patients with poorly controlled hypertension
[60].
There have been concerns among GPs and nurses that raising
awareness of CKD could have detrimental effects on patients
because of raised anxiety [22], but the current study provides a
model for informing patients about the diagnosis in the context of
the maintenance of general vascular health, with good evidence for
benefits in both clinical and quality of life outcomes and no
noticeable increase in anxiety. Broadening and personalising
discussions around kidney health may address fears over disease
labelling and support the practise of effective minimally disruptive
medicine [21] [32]. In light of recent clinical guidance, in addition
to the BRIGHT trial’s focus on placing CKD in the context of
general vascular health, patient and carer involvement in the
development of information resources to support the prevention
and management of acute kidney injury (AKI) may also be
warranted [61]. Elderly housebound patients living with complex
co-morbidities are particularly at risk of AKI - a syndrome that is
common, harmful, costly and potentially avoidable [62].
These findings provide support for an effective and cost-effective
strategy to improve outcomes for people with CKD and other
vascular diseases, which takes health management into everyday
contexts. Moving away from traditional individually-focused
models of self-management allows for appreciation of the everyday
challenges faced by people with long-term conditions and draws
attention towards potentially valuable forms of non-clinical
support [12].
Conclusions
Findings that an intervention delivered outside the health
encounter can have a significant (albeit modest) impact on health
outcomes and can be cost effective demonstrate the merit of a
community focussed approach to self-management support. The
BRIGHT trial highlights the potential importance of widening the
types of support offered to people with long-term conditions, in
particular by shifting the emphasis of self-management support
towards community resources and personal networks of support.
Although further work on mechanisms of effect is clearly
warranted, these findings, alongside evidence that interventions
to change professional behaviour to support self-management are
of limited benefit, suggest that better outcomes may be achieved
by placing more effort and resources in communities and that
more research should be directed towards determining ways and
means of embedding health management activities into everyday
life.
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